How to cite item

BRAF inhibitors in advanced BRAF-positive non-small cell lung cancer

   
@article{TCR11284,
	author = {Tiziana Vavalà},
	title = {BRAF inhibitors in advanced BRAF-positive non-small cell lung cancer},
	journal = {Translational Cancer Research},
	volume = {5},
	number = {Suppl 7},
	year = {2016},
	keywords = {},
	abstract = {The importance of biological target-based studies is currently highlighted by impressive objective response rates (ORRs) and longer progression-free survivals (PFSs) provided by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) compared with cytotoxic chemotherapies in the treatment of EGFR mutated non-small cell lung cancer (NSCLC) patients and, more recently, by anaplastic lymphoma kinase inhibitors (ALK-Is) in ALK-rearranged NSCLC ones (1-4). As a consequence, recent therapeutic research strategies in NSCLC, particularly in lung adenocarcinoma, focused on innovative potential molecular targets such as KRAS, BRAF, HER2, PIK3CA, and others in frequencies exceeding 1% (5).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/11284}
}